Zacks: Cumberland Pharmaceuticals, Inc. (CPIX) Given Average Recommendation of “Strong Buy” by Analysts

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus price target of $10.00 for the company and are expecting that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also given Cumberland Pharmaceuticals an industry rank of 39 out of 255 based on the ratings given to related companies.

Separately, TheStreet raised shares of Cumberland Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Wednesday, April 10th.

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Stonepine Capital Management LLC lifted its stake in shares of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) by 7.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,313,429 shares of the specialty pharmaceutical company’s stock after acquiring an additional 95,028 shares during the period. Cumberland Pharmaceuticals accounts for about 7.0% of Stonepine Capital Management LLC’s portfolio, making the stock its 4th largest position. Stonepine Capital Management LLC owned approximately 8.46% of Cumberland Pharmaceuticals worth $7,920,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 32.30% of the company’s stock.

Shares of CPIX traded down $0.04 during midday trading on Friday, reaching $5.82. The stock had a trading volume of 1,301 shares, compared to its average volume of 11,619. Cumberland Pharmaceuticals has a one year low of $4.83 and a one year high of $7.29. The company has a market cap of $89.90 million, a PE ratio of -48.50 and a beta of 0.31. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.13 and a quick ratio of 1.69.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, February 26th. The specialty pharmaceutical company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.24. Cumberland Pharmaceuticals had a negative net margin of 17.09% and a negative return on equity of 3.08%. The company had revenue of $13.50 million during the quarter, compared to the consensus estimate of $10.98 million. Analysts expect that Cumberland Pharmaceuticals will post -0.24 earnings per share for the current year.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Further Reading: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Cumberland Pharmaceuticals (CPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with's FREE daily email newsletter.